Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;133(4):592-601.
doi: 10.1309/AJCPS1K0OHLJYWWV.

Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma

Affiliations

Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma

Haipeng Shao et al. Am J Clin Pathol. 2010 Apr.

Abstract

Little information exists regarding the detection of minimal residual disease (MRD) in adult T-cell leukemia/lymphoma (ATLL). We evaluated 75 peripheral blood samples from 17 ATLL cases using flow cytometry (FC); 50 of the samples were concurrently evaluated by polymerase chain reaction (PCR) for clonal T-cell receptor gamma chain (TRG) gene rearrangement and the presence of human T-cell lymphotropic virus-1 proviral sequences. Residual ATLL cells were identified using a multiparametric approach to identify aberrant T-cell immunophenotypes. Malignant T cells were CD4+, CD3 dim+, CD26-, CD25 bright, CD7+, and CD27+, with occasional dim expression of CD2 or CD5. FC exhibited a high sensitivity, detecting as few as 0.29% ATLL cells/WBC (4.9 cells/microL) in the peripheral blood. PCR for TRG gene rearrangement was slightly more sensitive, and FC and PCR complemented each other in detecting MRD. In 2 patients, there was complete remission; 4 patients had disease refractory to therapy, and 3 died; 11 others had persistent disease with variable numbers of ATLL cells in the peripheral blood. Higher levels of ATLL cells appeared to correlate with disease severity. FC detection of aberrant T cells permits sensitive and quantitative monitoring of MRD in ATLL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Minimal residual disease (CD26−/CD4+ cells) in 17 patients with adult T-cell leukemia/lymphoma (ATLL). The time shown on the right is the follow-up period. Patients 4, 7, and 8 were unresponsive to treatment and died of disease progression. Patient 15 continued with daclizumab treatment after initial treatment with denileukin diftitox.
Image 1
Image 1
Representative flow cytometric analysis of adult T-cell leukemia/lymphoma cells in peripheral blood samples. The lymphoid cells were gated by forward light scatter vs side light scatter. The leukemic cells are indicated in red. A, The leukemic cells show typical immunophenotype: CD3 dim/CD7−/CD4+/CD25+/CD26−. B, The leukemic cells displayed a nearly normal level of expression of CD3 with a small subset dim for CD3 and were CD4+ and CD7−/CD26−. C, The leukemic cells were partially positive for CD7, slightly dim for CD3, and CD4+/CD26−. APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin chlorophyll protein.

Similar articles

Cited by

References

    1. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet. 1999;353:1951–1958. - PubMed
    1. Bangham CR. HTLV-1 infections. J Clin Pathol. 2000;53:581–586. - PMC - PubMed
    1. Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I–leukemia/lymphoma. Curr Treat Options Oncol. 2001;2:291–300. - PubMed
    1. Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer. 1989;43:250–253. - PubMed
    1. Yamaguchi K Human T-lymphotropic virus type I in Japan. Lancet. 1994;343:213–216. - PubMed

Publication types